Background: Prostate cancer (PCa) is prone to lymph node metastasis. In this report, the authors described a model predictive of the probability of lymph node metastasis in prostate cancer patients. Methods: Two-hundred seventy-eight middle-high-risk PCa patients who received laparoscopic radical prostatectomy (LRP) combined with extended pelvic lymph node dissection (e-PLND) in our hospital were selected as the subjects and the authors performed a retrospective analysis. According to the postoperative pathological results, the patients were divided into a pelvic lymph node metastasis group (n=100) and a non-pelvic lymph node metastasis group (n=178). Univariable and multivariable logistic regression analyses were performed to identify independent risk factors for pelvic lymph node metastasis from PCa. Finally, a clinical prediction model nomogram was further established and verified, and a calibration plot was drawn to verify the accuracy of the model. Results: The TPSA level, FPSA level, PI-RADS score, biopsy ISUP classification and Gleason score of the two groups were statistically different (P<0.05), and there was no statistical difference between the age groups (P>0.05). Receiver operating characteristic curve (ROC) showed that the best diagnostic cut-off value of TPSA was 77.45 ng/ml (AUC=0.785, 95%CI: 0.729-0.842), and the best diagnostic cut-off value of FPSA was 0.085 ng/ml (AUC=0.282, 95%CI: 0.215-0.348). Univariable and multivariable logistic regression analyses showed that, TPSA level (OR=1.00, 95%Cl: 1.000-1.006, P<0.05), FPSA level (OR=0.00, 95%Cl: 0.000-0.089, P<0.01), PI-RADS score (OR=9.26, 95%CI: 5.278-16.248, P<0.01) and biopsy ISUP grade (OR=1.69, 95%CI: 1.163-2.450, P<0.01) were independent predictors of pelvic lymph node metastasis. Conclusions: The nomogram established in this study has a good predictive ability for pelvic lymph node metastasis in patients with PCa, and can provide a reference for the selection of clinical treatment options.
Published in | International Journal of Clinical Urology (Volume 6, Issue 1) |
DOI | 10.11648/j.ijcu.20220601.13 |
Page(s) | 10-14 |
Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
Copyright |
Copyright © The Author(s), 2022. Published by Science Publishing Group |
Prostate Cancer, Pelvic Lymph Node Metastasis, Risk Factors, Nomogram
[1] | WILCZAK W, WITTMER C, CLAUDITZ T, et al. Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer [J]. European urology, 2018, 74 (3): 376-386. DOI: 10.1016/j.eururo.2018.05.034. |
[2] | WOLF J S, JR., CHER M, DALL'ERA M, et al. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy [J]. The Journal of urology, 1995, 153 (3 Pt 2): 993-999. PMID- 7853590. |
[3] | KATZ S, ROSEN M. MR imaging and MR spectroscopy in prostate cancer management [J]. Radiologic clinics of North America, 2006, 44 (5): 723-734, viii. DOI: 10.1016/j.rcl.2006.07.008. |
[4] | TEMPANY C M, MCNEIL B J. Advances in biomedical imaging [J]. Jama, 2001, 285 (5): 562-567. DOI: 10.1001/jama.285.5.562. |
[5] | CHAN T Y, PARTIN A W, WALSH P C, et al. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy [J]. Urology, 2000, 56 (5): 823-827. DOI: 10.1016/s0090-4295(00)00753-6. |
[6] | STARK J R, PERNER S, STAMPFER M J, et al. Gleason score and lethal prostate cancer: does 3 + 4=4 + 3? [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2009, 27 (21): 3459-3464. DOI: 10.1200/JCO.2008.20.4669. |
[7] | O'BRIEN B A, COHEN R J, WHEELER T M, et al. A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis [J]. BJU international, 2011, 107 (3): 389-395. DOI: 10.1200/JCO.2012.41.5984. |
[8] | WANG Y, LI J, XIA Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy [J]. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2013, 31 (9): 1188-1195. DOI: 10.21037/jtd.2018.03.126. |
[9] | YANG X, PAN X, LIU H, et al. A new approach to predict lymph node metastasis in solid lung adenocarcinoma: a radiomics nomogram [J]. Journal of thoracic disease, 2018, 10 (Suppl 7): S807-s19. DOI: 10.1111/j.1464-410X.2010.09539.x. |
[10] | DANIYAL M, SIDDIQUI Z A, AKRAM M, et al. Epidemiology, etiology, diagnosis and treatment of prostate cancer [J]. Asian Pacific journal of cancer prevention: APJCP, 2014, 15 (22): 9575-9578. DOI: 10.7314/apjcp.2014.15.22.9575. |
[11] | DANESHMAND S, QUEK M L, STEIN J P, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results [J]. The Journal of urology, 2004, 172 (6 Pt 1): 2252-2255. DOI: 10.1097/01.ju.0000143448.04161.cc. |
[12] | MOTTET N, BELLMUNT J, BOLLA M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent [J]. European urology, 2017, 71 (4): 618-629. DOI: 10.1016/j.crad.2007.05.022. |
[13] | PLOUSSARD G, BRIGANTI A, DE LA TAILLE A, et al. Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature [J]. European urology, 2014, 65 (1): 7-16. DOI: 10.1016/j.eururo.2016.08.003. |
[14] | FOSSATI N, WILLEMSE P M, VAN DEN BROECK T, et al. The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review [J]. European urology, 2017, 72 (1): 84-109. DOI: 10.1016/j.eururo.2013.03.057. |
[15] | HöVELS A M, HEESAKKERS R A, ADANG E M, et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis [J]. Clinical radiology, 2008, 63 (4): 387-395. DOI: 10.1016/j.eururo.2016.12.003. |
[16] | CIMINO S, REALE G, CASTELLI T, et al. Comparison between Briganti, Partin and MSKCC tools in predicting positive lymph nodes in prostate cancer: a systematic review and meta-analysis [J]. Scand J Urol, 2017, 51 (5): 345-350. DOI: 10.1080/21681805.2017.1332680. |
[17] | ZANELLI E, GIANNARINI G, CERESER L, et al. Head-to-head comparison between multiparametric MRI, the partin tables, memorial sloan kettering cancer center nomogram, and CAPRA score in predicting extraprostatic cancer in patients undergoing radical prostatectomy [J]. J Magn Reson Imaging, 2019, 50 (5): 1604-1613. DOI: 10.1002/jmri.26743. |
[18] | BANDINI M, FOSSATI N, GANDAGLIA G, et al. Neoadjuvant and adjuvant treatment in high-risk prostate cancer [J]. Expert Rev Clin Pharmacol, 2018, 11 (4): 425-438. DOI: 10.1080/17512433.2018.1429265. |
APA Style
Xu Yang, Chen Rui, Li Shuofeng, Zhang Chi, Zheng Yuxin, et al. (2022). A Nomogram for Predicting Pelvic Lymph Node Metastasis in Prostate Cancer. International Journal of Clinical Urology, 6(1), 10-14. https://doi.org/10.11648/j.ijcu.20220601.13
ACS Style
Xu Yang; Chen Rui; Li Shuofeng; Zhang Chi; Zheng Yuxin, et al. A Nomogram for Predicting Pelvic Lymph Node Metastasis in Prostate Cancer. Int. J. Clin. Urol. 2022, 6(1), 10-14. doi: 10.11648/j.ijcu.20220601.13
AMA Style
Xu Yang, Chen Rui, Li Shuofeng, Zhang Chi, Zheng Yuxin, et al. A Nomogram for Predicting Pelvic Lymph Node Metastasis in Prostate Cancer. Int J Clin Urol. 2022;6(1):10-14. doi: 10.11648/j.ijcu.20220601.13
@article{10.11648/j.ijcu.20220601.13, author = {Xu Yang and Chen Rui and Li Shuofeng and Zhang Chi and Zheng Yuxin and Li Wang}, title = {A Nomogram for Predicting Pelvic Lymph Node Metastasis in Prostate Cancer}, journal = {International Journal of Clinical Urology}, volume = {6}, number = {1}, pages = {10-14}, doi = {10.11648/j.ijcu.20220601.13}, url = {https://doi.org/10.11648/j.ijcu.20220601.13}, eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcu.20220601.13}, abstract = {Background: Prostate cancer (PCa) is prone to lymph node metastasis. In this report, the authors described a model predictive of the probability of lymph node metastasis in prostate cancer patients. Methods: Two-hundred seventy-eight middle-high-risk PCa patients who received laparoscopic radical prostatectomy (LRP) combined with extended pelvic lymph node dissection (e-PLND) in our hospital were selected as the subjects and the authors performed a retrospective analysis. According to the postoperative pathological results, the patients were divided into a pelvic lymph node metastasis group (n=100) and a non-pelvic lymph node metastasis group (n=178). Univariable and multivariable logistic regression analyses were performed to identify independent risk factors for pelvic lymph node metastasis from PCa. Finally, a clinical prediction model nomogram was further established and verified, and a calibration plot was drawn to verify the accuracy of the model. Results: The TPSA level, FPSA level, PI-RADS score, biopsy ISUP classification and Gleason score of the two groups were statistically different (P0.05). Receiver operating characteristic curve (ROC) showed that the best diagnostic cut-off value of TPSA was 77.45 ng/ml (AUC=0.785, 95%CI: 0.729-0.842), and the best diagnostic cut-off value of FPSA was 0.085 ng/ml (AUC=0.282, 95%CI: 0.215-0.348). Univariable and multivariable logistic regression analyses showed that, TPSA level (OR=1.00, 95%Cl: 1.000-1.006, PConclusions: The nomogram established in this study has a good predictive ability for pelvic lymph node metastasis in patients with PCa, and can provide a reference for the selection of clinical treatment options.}, year = {2022} }
TY - JOUR T1 - A Nomogram for Predicting Pelvic Lymph Node Metastasis in Prostate Cancer AU - Xu Yang AU - Chen Rui AU - Li Shuofeng AU - Zhang Chi AU - Zheng Yuxin AU - Li Wang Y1 - 2022/01/26 PY - 2022 N1 - https://doi.org/10.11648/j.ijcu.20220601.13 DO - 10.11648/j.ijcu.20220601.13 T2 - International Journal of Clinical Urology JF - International Journal of Clinical Urology JO - International Journal of Clinical Urology SP - 10 EP - 14 PB - Science Publishing Group SN - 2640-1355 UR - https://doi.org/10.11648/j.ijcu.20220601.13 AB - Background: Prostate cancer (PCa) is prone to lymph node metastasis. In this report, the authors described a model predictive of the probability of lymph node metastasis in prostate cancer patients. Methods: Two-hundred seventy-eight middle-high-risk PCa patients who received laparoscopic radical prostatectomy (LRP) combined with extended pelvic lymph node dissection (e-PLND) in our hospital were selected as the subjects and the authors performed a retrospective analysis. According to the postoperative pathological results, the patients were divided into a pelvic lymph node metastasis group (n=100) and a non-pelvic lymph node metastasis group (n=178). Univariable and multivariable logistic regression analyses were performed to identify independent risk factors for pelvic lymph node metastasis from PCa. Finally, a clinical prediction model nomogram was further established and verified, and a calibration plot was drawn to verify the accuracy of the model. Results: The TPSA level, FPSA level, PI-RADS score, biopsy ISUP classification and Gleason score of the two groups were statistically different (P0.05). Receiver operating characteristic curve (ROC) showed that the best diagnostic cut-off value of TPSA was 77.45 ng/ml (AUC=0.785, 95%CI: 0.729-0.842), and the best diagnostic cut-off value of FPSA was 0.085 ng/ml (AUC=0.282, 95%CI: 0.215-0.348). Univariable and multivariable logistic regression analyses showed that, TPSA level (OR=1.00, 95%Cl: 1.000-1.006, PConclusions: The nomogram established in this study has a good predictive ability for pelvic lymph node metastasis in patients with PCa, and can provide a reference for the selection of clinical treatment options. VL - 6 IS - 1 ER -